Mankind Pharma Limited (NSE:MANKIND) dispatched a Postal Ballot Notice on August 18, 2026, seeking shareholder approval through remote e-voting to appoint Mr. Anish Vanraj Bafna (DIN: 02925792) as a Non-Executive Independent Director for a five-year term commencing August 10, 2026.
Key Highlights
- The board appointed Mr. Anish Vanraj Bafna as an Additional Director designated Non-Executive Independent Director with effect from August 10, 2026, subject to shareholder ratification via Special Resolution.
- The e-voting window opens on Wednesday, August 19, 2026, at 9:00 AM IST and closes on Thursday, September 17, 2026, at 5:00 PM IST.
- The cut-off date for determining shareholder eligibility to vote is Friday, August 14, 2026, as recorded in the register of members and depository records.
- Results of the postal ballot are to be declared on or before Monday, September 21, 2026, and will be uploaded on the company's website and stock exchange portals.
About the Company
Mankind Pharma Limited (NSE:MANKIND), headquartered at Okhla Industrial Estate, New Delhi, is one of India's leading pharmaceutical companies. It develops, manufactures, and markets branded generic formulations across therapeutic areas including cardiovascular, anti-diabetic, respiratory, and anti-infective segments. The company distributes its products through an extensive field force spanning urban and rural geographies across India.
Announcement in Detail
The Postal Ballot Notice, dated August 10, 2026, was dispatched electronically on August 18, 2026, to members whose names appeared in the register of members or depository records as on the cut-off date of August 14, 2026. The notice proposes a single Special Resolution: the appointment of Mr. Anish Vanraj Bafna (DIN: 02925792) as a Non-Executive Independent Director for a term of five consecutive years from August 10, 2026, not liable to retire by rotation.
The appointment follows a recommendation by the Nomination and Remuneration Committee, and Mr. Bafna has submitted a declaration confirming he meets the independence criteria under Section 149(6) of the Companies Act, 2013, and Regulation 16(1)(b) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. He will be entitled to sitting fees, expense reimbursement, and profit-related commission within limits prescribed under Sections 197 and 198 of the Act. National Securities Depository Limited (NSDL) is facilitating the e-voting process, and Mr. Neelesh Kumar Jain of M/s. N.K.J. and Associates has been appointed as the independent scrutiniser.
Impact on Investors
Investors will note that this resolution is a governance matter requiring a Special Resolution, meaning it must pass with at least 75% of votes cast in favour. The filing shows that only shareholders recorded as on the cut-off date of August 14, 2026, are entitled to participate in e-voting, with voting rights proportional to their paid-up equity shareholding on that date. Shareholders who did not have their email addresses registered with the company or depositories as of that date would not have received the electronic notice, though it remains available on the company website and exchange portals.
The disclosed terms indicate that Mr. Bafna's appointment as a Non-Executive Independent Director does not involve any equity issuance or dilution. The addition of an independent director, if approved, would affect the composition of the board and its committees in accordance with SEBI listing norms on board independence.
Sector / Market Context
India's pharmaceutical sector operates under heightened regulatory scrutiny on corporate governance following SEBI's ongoing efforts to strengthen board independence norms. SEBI's LODR Regulations mandate that listed companies maintain a minimum proportion of independent directors on their boards, and the appointment of independent directors through shareholder-approved processes forms a core pillar of these disclosure and governance standards. The domestic formulations market, in which Mankind Pharma competes, has historically required companies with broad retail distribution networks to maintain strong internal oversight structures, making board composition a recurring area of focus in annual filings and investor interactions.